Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease

25 Feb 2016

Abstract excerpt

BACKGROUND: Human papillomavirus (HPV) has been identified as the primary etiologic factor of cervical cancer as well as subsets of anogenital and oropharyngeal cancers. The two HPV viral oncoproteins, E6 and E7, are uniquely and consistently expressed in all HPV infected cells and are therefore promising targets for therapeutic vaccination. Both recombinant naked DNA and protein-based HPV vaccines have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Immunotherapy and Immune Responses
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26918115
DOI: 10.1186/s13578-016-0080-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated diseasePMID 26918115Read ↗

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.Semantic proximity Read ↗

Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope VaccineSemantic proximity Read ↗

Customized Viral Immunotherapy for HPV-Associated Cancer.Semantic proximity Read ↗

Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteinsSemantic proximity Read ↗

DNA vaccines for cervical cancer: from bench to bedsideSemantic proximity Read ↗

Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell ResponsesSemantic proximity Read ↗

A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.Semantic proximity Read ↗

Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 proteinSemantic proximity Read ↗

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approachesSemantic proximity Read ↗

Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6Semantic proximity Read ↗

A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effectsSemantic proximity Read ↗

Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.